Here, we evaluated in vitro and in vivo the effectiveness of a new combinatorial therapeutic strategy, based on the inhibition of xCT together with APR-246 treatment, with the aim of restoring the wild-type form of p53 in different breast cancer cell lines. This evidence concerns the gene SLC7A11 and breast cancer.